Journal of comparative effectiveness research

01 19 October 2026

DOI 10.57264/cer-2026-0183

Response to Letter to the Editor regarding “Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema”

Open DOI

Yinglei Li, Simona Gavata-Steiger, Chiara Nenci et al.

02 19 October 2026

DOI 10.57264/cer-2026-0018

Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema

Open DOI

Irmgard Andresen, Natalie Khutoryansky, Sarah L Feeny et al.

03 19 October 2026

DOI 10.57264/cer-2026-0215

Corrigendum

Open DOI

04 15 October 2026

DOI 10.57264/cer-2026-0103

Methodological considerations for indirect treatment comparisons of HIV incidence for long-acting injectable pre-exposure prophylaxis

Open DOI

Tristan Curteis, Aidan N Franklin, Rebecca K Judge et al.

Background: Given the effectiveness of pre-exposure prophylaxis (PrEP), the HIV prevention landscape is expanding rapidly – including recently approved injectable options which have shown high efficacy in clinical trials. As head-to-head...

Read abstract

05 13 October 2026

DOI 10.57264/cer-2026-0146

Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China

Open DOI

Genyong Zuo, Aijun Liu, Zunmin Zhu et al.

Aim: Expanding treatment options for transplant-ineligible newly diagnosed multiple myeloma (ndMM) in China has increased the need to identify treatment strategies that improve patient outcomes while using healthcare resources efficientl...

Read abstract

06 9 October 2026

DOI 10.57264/cer-2026-0077

Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studies

Open DOI

Batyrkhan Kuatov, Barkha P Patel, Muhaimen Siddiqui et al.

Aim: In the absence of direct evidence, indirect treatment comparisons (ITCs) serve as a tool for comparing treatment efficacy to guide evidence-based healthcare decisions. As an example, given the growing number of treatments available ...

Read abstract

07 8 October 2026

DOI 10.57264/cer-2026-0142

Development and implementation of a living network meta-analysis framework for comparative effectiveness research: a case study in chronic venous insufficiency treatment

Open DOI

Wendy Wifler, Dirk Sutherland, Diana Frame et al.

Aim: To develop, implement and evaluate a living network meta-analysis (NMA) framework for comparative effectiveness research, using chronic venous insufficiency treatment as a case study. The framework addresses key barriers to sustaine...

Read abstract

08 6 October 2026

DOI 10.57264/cer-2026-0132

Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma

Open DOI

Renata Walewska, Kaijun Wang, Caitlin Smare et al.

Aim: Traditional management of relapsed or refractory (R/R) marginal zone lymphoma (MZL) comprises chemotherapy, rituximab or rituximab-based chemoimmunotherapy (CIT). Zanubrutinib, a Bruton tyrosine kinase inhibitor, has shown high over...

Read abstract

09 1 October 2026

DOI 10.57264/cer-2026-0120

On the economics of broadly neutralizing monoclonal antibodies for HIV prevention in high-income countries

Open DOI

Blythe Adamson, Huub C Gelderblom, Maurine D Miner et al.

Aim: To quantify the market opportunity and economic impact of broadly neutralizing monoclonal antibodies (bnAbs) as a novel HIV prevention modality in high-income countries. Materials & methods: Using a decision-tree and revenue model a...

Read abstract

10 1 October 2026

DOI 10.57264/cer-2026-0138

Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome

Open DOI

Emmanuelle Kaltenbach, Alice Guiraud-Diawara, Jérémie Schwarzbard et al.

Aim: Alagille syndrome (ALGS) is a rare genetic disorder associated with cholestasis and subsequent severe pruritus, which significantly impacts patient quality of life (QoL). Odevixibat (ODX) and maralixibat (MRX) are ileal bile acid tr...

Read abstract